Chemomab Therapeutics News

Roth MKM Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Raises Target Price to $9

Moomoo NewsJul 26 08:31 ET · Ratings

Express News | Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement

ReutersJul 26 07:00 ET

ADRs Close Lower; Chemomab Therapeutics Ltd. Declines 16%

Dow JonesJul 25 16:30 ET

Oppenheimer Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Raises Target Price to $13

Moomoo NewsJul 25 15:32 ET · Ratings

Chemomab Therapeutics to Raise $10 Million From Private Placement; Shares Fall

MT NewswiresJul 25 14:04 ET

Express News | Chemomab Therapeutics: Purchase Agreement Post Which Agreed to Sell in Lieu of Adss, Pre-Funded Warrants to Purchase up to 3.1 Mln Adss

ReutersJul 25 08:14 ET

Chemomab Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)

SEC announcementJul 25 08:13 ET · Announcements

Express News | Chemomab Therapeutics: Purchase Agreement With Purchasers, Post Which Co Agreed to Sell 4.2 Mln Adss

ReutersJul 25 08:12 ET

Express News | Chemomab Therapeutics Reported Topline Results From The Phase 2 SPRING Trial Of CM-101 For Primary Sclerosing Cholangitis, Achieving Its Primary Endpoint Demonstrating Anti-fibrotic, Anti-inflammatory And Anti-cholestatic Effects

BenzingaJul 25 07:45 ET

Express News | Chemomab - Expects Pipe to Extend Cash Runway Through Beginning of 2026

ReutersJul 25 07:39 ET

Express News | Chemomab Therapeutics Announces $10 Million Private Placement

ReutersJul 25 07:38 ET

Express News | Chemomab Therapeutics Ltd - Cm-101 Demonstrates a Favorable Safety Profile

ReutersJul 25 07:00 ET

Express News | Chemomab Therapeutics Announces Positive Phase 2 Trial Results: Cm-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients With Primary Sclerosing Cholangitis

ReutersJul 25 07:00 ET

Express News | CHEMOMAB Granted U.S. Patent #12018074: Anti CCL24 (Eotaxin2) Antibodies for Use in the Treatment of Hepatic Diseases

BenzingaJun 25 15:43 ET

Roth MKM Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Maintains Target Price $7

Moomoo NewsJun 21 08:32 ET · Ratings

Maxim Group Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Maintains Target Price $4

moomoo NewsJun 19 14:31 ET · Ratings

Express News | Chemomab Therapeutics Announces New Publications Reinforcing the Clinical Potential of Its Ccl24-Neutralizing Antibody Cm-101 in Primary Sclerosing Cholangitis

ReutersJun 18 07:00 ET

Express News | Chemomab Therapeutics Shares Are Trading Lower. The Company Announced That It Presented Two Scientific Posters Supporting the Clinical Rationale for the Company's Primary Sclerosing Cholangitis Program at EASL 2024

BenzingaJun 6 12:39 ET

Express News | Chemomab Says It Presented Two Scientific Posters Supporting The Clinical Rationale For Company's Primary Sclerosing Cholangitis Program At EASL 2024, For The Study Of Liver

BenzingaJun 6 07:22 ET

Chemomab Therapeutics to Participate in Upcoming Scientific Conferences

GlobeNewswireMay 17 07:00 ET